Arena Pharmaceuticals, Inc.
NEWS
Arena Pharmaceuticals was acquired by Pfizer in March 2022.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval.
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
Arena Pharmaceuticals released positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
IN THE PRESS